Genetic deletion or antagonism of kinin B1 and B2 receptors improves cognitive deficits in a mouse model of Alzheimer's disease

Neuroscience

Volumn 151, Issue 3, 2008, Pages 631-643

  Prediger, R D S ^a   Medeiros, R ^a   Pandolfo, P ^a   Duarte, F S ^a   Passos, G F ^a   Pesquero, J B ^b   Campos, M M ^c   Calixto, J B ^a   Takahashi, R N ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

amyloid peptide; Alzheimer's disease; B1 and B2 receptor; bradykinin; knockout mice; spatial learning and memory

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; BRADYKININ B1 RECEPTOR; BRADYKININ B1 RECEPTOR ANTAGONIST; BRADYKININ B2 RECEPTOR; ICATIBANT;

ALZHEIMER DISEASE; AMNESIA; ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN REGION; COGNITIVE DEFECT; CONTROLLED STUDY; GENE DELETION; HIPPOCAMPUS; LEARNING; MALE; MAZE TEST; MOUSE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; BRADYKININ; CEREBRAL CORTEX; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EXPLORATORY BEHAVIOR; HIPPOCAMPUS; MALE; MAZE LEARNING; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PEPTIDE FRAGMENTS; REACTION TIME; RECEPTOR, BRADYKININ B1; RECEPTOR, BRADYKININ B2; TIME FACTORS;

EID: 38949158726     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2007.11.009     Document Type: Article

References (59)

1. Akiyama H., Arai T., Kondo H., Tanno E., Haga C., and Ikeda K. Cell mediators of inflammation in the Alzheimer disease brain. Alzheimer Dis Assoc Disord 14 (2000) S47-S53
2. Arendash G.W., Lewis J., Leighty R.E., McGowan E., Cracchiolo J.R., Hutton M., and Garcia M.F. Multi-metric behavioral comparison of Appsw and P301L models for Alzheimer's disease: linkage of poorer cognitive performance to tau pathology in forebrain. Brain Res 1012 (2004) 29-41
3. Augustinack J.C., Schneider A., Mandelkow E.M., and Hyman B.T. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol 103 (2002) 26-35
4. Bauer J., Strauss S., Schreiter-Gasser U., Ganter U., Schlegel P., Witt I., Yolk B., and Berger M. Interleukin-6 and alpha-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices. FEBS Lett 285 (1991) 111-114
5. Bergamaschini L., Donarini C., Foddi C., Gobbo G., Pametti L., and Agostoni A. The region 1-11 of Alzheimer amyloid-beta is critical for activation of contact-kinin system. Neurobiol Aging 22 (2001) 63-69
6. Calixto J.B., Cabrini D.A., Ferreira J., and Campos M.M. Kinins in pain and inflammation. Pain 87 (2000) 1-5
7. Calixto J.B., Medeiros R., Fernandes E.S., Ferreira J., Cabrini D.A., and Campos M.M. Kinin B1 receptors: key G-protein-coupled receptors and their role in inflammatory and painful processes. Br J Pharmacol 143 (2004) 803-818
8. Campos M.M., Leal P.C., Yunes R.A., and Calixto J.B. Non-peptide antagonists for kinin B1 receptors: new insights into their therapeutic potential for the management of inflammation and pain. Trends Pharmacol Sci 27 (2006) 646-651
9. Chen E.Y., Emerich D.F., Bartus R.T., and Kordower J.H. B2 bradykinin receptor immunoreactivity in rat brain. J Comp Neurol 427 (2000) 1-18
10. Cho H.S., Hyman B.T., Greenberg S.M., and Rebeck G.W. Quantification of apoE domains in Alzheimer disease brain suggests a role for apoE in Abeta aggregation. J Neuropathol Exp Neurol 60 (2001) 342-349
11. Correa F.M., Innis R.B., Uhl G.R., and Snyder S.H. Bradykinin-like immunoreactive neuronal systems localized histochemically in rat brain. Proc Natl Acad Sci U S A 76 (1979) 1489-1493
12. Da Cunha C., Wietzikoski S., Wietzikoski E.C., Miyoshi E., Ferro M.M., Anselmo-Franci J.A., and Canteras N.S. Evidence for the substantia nigra pars compacta as an essential component of a memory system independent of the hippocampal memory system. Neurobiol Learn Mem 79 (2003) 236-242
13. DiMattia B.D., and Kesner R.P. Spatial cognitive maps: differential role of parietal cortex and hippocampal formation. Behav Neurosci 102 (1988) 471-480
14. Ferreira J., Beirith A., Mori M.A., Araujo R.C., Bader M., Pesquero J.B., and Calixto J.B. Reduced nerve injury-induced neuropathic pain in kinin B1 receptor knock-out mice. J Neurosci 25 (2005) 2405-2412
15. Ferreira J., Campos M.M., Araujo R., Bader M., Pesquero J.B., and Calixto J.B. The use of kinin B1 and B2 receptor knockout mice and selective antagonists to characterize the nociceptive responses caused by kinins at the spinal level. Neuropharmacology 43 (2002) 1188-1197
16. Fillit H., Ding W.H., Buee L., Kalman J., Altstiel L., Lawlor B., and Wolf-Klein G. Elevated circulating tumor necrosis factor levels in Alzheimer's disease. Neurosci Lett 129 (1991) 318-320
17. Flood J.F., Morley J.E., and Roberts E. Amnestic effects in mice of four synthetic peptides homologous to amyloid β protein from patients with Alzheimer's disease. Proc Natl Acad Sci U S A 88 (1991) 3363-3366
18. Franklin K.B.J., and Paxinos G. The mouse brain in stereotaxic coordinates (1997), Academic Press, San Diego
19. Griffin W.S., Sheng J.G., Royston M.C., Gentleman S.M., McKenzie J.E., Graham D.I., Roberts G.W., and Mrak R.E. Glial-neuronal interactions in Alzheimer's disease: the potential role of a "cytokine cycle" in disease progression. Brain Pathol 8 (1998) 65-72
20. Haass C., and De Strooper B. The presenilins in Alzheimer's disease: proteolysis holds the key. Science 286 (1999) 916-919
21. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., and Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274 (1996) 99-102
22. Huang H.M., Lin T.A., Sun G.Y., and Gibson G.E. Increased inositol 1,4,5-trisphophate accumulation correlates with an up-regulation of bradykinin receptors in Alzheimer's disease. J Neurochem 64 (1995) 761-766
23. Huang H.M., Ou H.C., and Hsueh S.J. Amyloid beta peptide enhanced bradykinin-mediated inositol (1,4,5)trisphosphate formation and cytosolic free calcium. Life Sci 63 (1998) 195-203
24. Hull M., Lieb K., and Fiebich B.L. Anti-inflammatory drugs: a hope for Alzheimer's disease?. Expert Opin Investig Drugs 9 (2000) 671-683
25. Hyman B.T., Gomez-Isla T., Rebeck G.W., Briggs M., Chung H., West H.L., Greenberg S., Mui S., Nichols S., Wallace R., and Growdon J.H. Epidemiological, clinical, and neuropathological study of apolipoprotein E genotype in Alzheimer's disease. Ann N Y Acad Sci 802 (1996) 1-5
26. Iores-Marçal L.M., Viel T.A., Buck H.S., Nunes V.A., Gozzo A.J., Cruz-Silva I., Miranda A., Shimamoto K., Ura N., and Araujo M.S. Bradykinin release and inactivation in brain of rats submitted to an experimental model of Alzheimer's disease. Peptides 27 (2006) 3363-3369
27. Irizarry M.C., Deng A., Lleo A., Berezovska O., Von Amim C.A., Martin-Rehrmann M., Manelli A., LaDu M.J., Hyman B.T., and Rebeck G.W. Apolipoprotein E modulates gamma-secretase cleavage of the amyloid precursor protein. J Neurochem 90 (2004) 1132-1143
28. Jhoo J.H., Kim H.C., Nabeshima T., Yamada K., Shin E.J., Jhoo W.K., Kim W., Kang K.S., Jo S.A., and Woo J.I. Beta-amyloid (1-42)-induced learning and memory deficits in mice: involvement of oxidative burdens in the hippocampus and cerebral cortex. Behav Brain Res 155 (2004) 185-196
29. Jong Y.J., Ford S.R., Seehra K., Malave V.B., and Baenziger N.L. Alzheimer's disease skin fibroblasts selectively express a bradykinin signalling pathway mediating tau protein Ser phosphorylation. FASEB J 17 (2003) 2319-2321
30. Joseph K., Shibayama Y., Nakazawa Y., Peerschke E.I., Ghebrehiwet B., and Kaplan A.P. Interaction of factor XII and high molecular weight kininogen with cytokeratin 1 and gC1qR of vascular endothelial cells and with aggregated Abeta protein of Alzheimer's disease. Immunopharmacology 43 (1999) 203-210
31. Laursen S.E., and Belknap J.K. Intracerebroventricular injections in mice. Some methodological refinements. J Pharmacol Methods 16 (1986) 355-357
32. Leeb-Lundberg L.M., Marceau F., Muller-Esterl W., Pettibone D.J., and Zuraw B.L. International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev 57 (2005) 27-77
33. Marceau F., Hess J.F., and Bachvarov D.R. The B1 receptors for kinins. Pharmacol Rev 50 (1998) 357-386
34. Maurice T., Lockhart B.P., and Privat A. Amnesia induced in mice by centrally administered beta-amyloid peptides involves cholinergic dysfunction. Brain Res 706 (1996) 181-193
35. McGeer P.L., Schulzer M., and McGeer E.G. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 47 (1996) 425-432
36. Medeiros R., Cabrini D.A., Ferreira J., Fernandes E.S., Mori M.A., Pesquero J.B., Bader M., Avellar M.C., Campos M.M., and Calixto J.B. Bradykinin B1 receptor expression induced by tissue damage in the rat portal vein: a critical role for mitogen-activated protein kinase and nuclear factor-kappaB signalling pathways. Circ Res 94 (2004) 1375-1382
37. Medeiros R., Prediger R.D., Passos G.F., Pandolfo P., Duarte F.S., Franco J.L., Dafre A.L., Di Giunta G., Figueiredo C.P., Takahashi R.N., Campos M.M., and Calixto J.B. Connecting TNF-α signaling pathways to iNOS expression in a mouse model of Alzheimer's disease: relevance for the behavioral and synaptic deficits induced by amyloid β protein. J Neurosci 27 (2007) 5394-5404
38. Moreau M.E., Garbacki N., Molinaro G., Brown N.J., Marceau F., and Adam A. The kallikrein-kinin system: current and future pharmacological targets. J Pharmacol Sci 99 (2005) 6-38
39. Morris R.G.M., Garrud P., Rawlins J.N.P., and O'Keefe J. Place navigation impaired in rats with hippocampal lesions. Nature 297 (1992) 681-683
40. Nitsch R.M., Kim C., and Growdon J.H. Vasopressin and bradykinin regulate secretory processing of the amyloid protein precursor of Alzheimer's disease. Neurochem Res 23 (1998) 807-814
41. Nitta A., Itoh A., Hasegawa T., and Nabeshima T. β-Amyloid protein-induced Alzheimer's disease animal model. Neurosci Lett 170 (1994) 63-66
42. Packard M.G., and McGaugh J.L. Inactivation of hippocampus or caudate nucleus with lidocaine differentially affects expression of place and response learning. Neurobiol Learn Mem 65 (1996) 65-72
43. Pesquero J.B., Araujo R.C., Heppenstall P.A., Stucky C.L., Silva Jr. J.A., Walther T., Oliveira S.M., Pesquero J.L., Paiva A.C., Calixto J.B., Lewin G.R., and Bader M. Hypoalgesia and altered inflammatory responses in mice lacking kinin B1 receptors. Proc Natl Acad Sci U S A 97 (2000) 8140-8145
44. Prat A., Biernacki K., Pouly S., Nalbantoglu J., Couture R., and Antel J.P. Kinin B1 receptor expression and function on human brain endothelial cells. J Neuropathol Exp Neurol 59 (2000) 896-906
45. Prat A., Weinrib L., Becher B., Poirier J., Duquette P., Couture R., and Antel J.P. Bradykinin B1 receptor expression and function on T lymphocytes in active multiple sclerosis. Neurology 53 (1999) 2087-2092
46. Prediger R.D., Franco J.L., Pandolfo P., Medeiros R., Duarte F.S., Di Giunta G., Figueiredo C.P., Farina M., Calixto J.B., Takahashi R.N., and Dafre A.L. Differential susceptibility following beta-amyloid peptide-(1-40) administration in C57BL/6 and Swiss albino mice: Evidence for a dissociation between cognitive deficits and the glutathione system response. Behav Brain Res 177 (2007) 205-213
47. Racchi M., Ianna P., Binetti G., Trabucchi M., and Govoni S. Bradykinin-induced amyloid precursor protein secretion: a protein kinase C-independent mechanism that is not altered in fibroblasts from patients with sporadic Alzheimer's disease. Biochem J 330 (1998) 1271-1275
48. Raidoo D.M., and Bholla K.D. Kinin receptors on human neurones. J Neuroimmunol 77 (1997) 39-44
49. 8 bradykinin and genetic disruption of the B2 receptor on nociception in rats and mice. Pain 71 (1997) 89-97
50. Selkoe D. The molecular pathology of Alzheimer's disease. Neuron 6 (1991) 487-498
51. Terranova J.P., Kan J.P., Storme J.J., Perreaut P., Le Fur G., and Soubrie P. Administration of amyloid β-peptides in the rat medial septum causes memory deficits: reversal by SR 57746A, a non-peptide neurotrophic compound. Neurosci Lett 213 (1996) 79-82
52. Tuppo E.E., and Arias H.R. The role of inflammation in Alzheimer's disease. Int J Biochem Cell Biol 37 (2005) 289-305
53. Vam Dam D., and De Deyn P.P. Drug discovery in dementia: the role of rodent models. Nat Rev Drug Discov 5 (2006) 956-970
54. Viel TA, Lima Caetano A, Nasello AG, Lancelotti CL, Nunes VA, Araujo MS, Buck HS (2007) Increases of kinin B(1) and B(2) receptors binding sites after brain infusion of amyloid-beta 1-40 peptide in rats. Neurobiol Aging, in press.
55. Walker K., Perkins M., and Dray A. Kinins and kinin receptors in the nervous system. Neurochem Int 26 (1995) 1-16
56. Walsh D.M., and Selkoe D.J. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 44 (2004) 181-193
57. Westerman M.A., Cooper-Blacketer D., Mariash A., Kotilinek L., Kawarabayashi T., Younkin L.H., Carlson G.A., Younkin S.G., and Ashe K.H. The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci 22 (2002) 1858-1867
58. Wirth K.J., Fink E., Rudolphi K., Heitsch H., Deutschlander N., and Wiemer G. Amyloid beta-(1-40) stimulates cyclic GMP production via release of kinins in primary cultured endothelial cells. Eur J Pharmacol 382 (1999) 27-33
59. Yan J.J., Cho J.Y., Kim H.S., Kim K.L., Jung J.S., Huh S.O., Suh H.W., Kim Y.H., and Song D.K. Protection against beta-amyloid peptide toxicity in vivo with long-term administration of ferulic acid. Br J Pharmacol 133 (2001) 89-96